Citius pharmaceuticals, inc. provides first half 2021 business update, highlights upcoming milestones

Cranford, n.j., july 7, 2021 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today provided a business update for the six-month period ended june 30, 2021 and reported on recent corporate developments.
CTXR Ratings Summary
CTXR Quant Ranking